GOGO AI NETWORK INC.
(formerly MedBright AI Investments Inc.)

Condensed Interim Consolidated Financial Statements

For the three months ended May 31, 2026 and 2025

(Expressed in Canadian dollars)
(Unaudited – Prepared by Management)

NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

In accordance with National Instrument 51-102 Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of these condensed interim consolidated financial statements, they must be accompanied by a notice indicating that the condensed interim consolidated financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements of the Company for the three months ended May 31, 2026 have been prepared by and are the responsibility of the Company's management, and have not been reviewed by the Company's auditors.

GOGO AI NETWORK INC.
(formerly MedBright AI Investments Inc.)
Consolidated Statements of Financial Position
As at May 31, 2026 and February 28, 2026
(Unaudited - Expressed in Canadian dollars)

		May 31, 2026 $	**February 28, 2026 $**
Assets			
Current assets			
Cash and cash equivalents		1,515,539	18,851
Prepaid expenses		32,478	29,864
Total current assets		1,548,017	48,715
Non-current asset			
Investments	5	5,021,372	2,260,532
Total non-current assets		5,021,372	2,260,532
Total assets		**6,569,389**	**2,309,247**
Liabilities			
Current liabilities			
Accounts payable and accrued liabilities	6	398,877	381,197
Loan payable	7	265,000	-
Total liabilities		**663,877**	**381,197**
Shareholders' equity			
Share capital	9	19,031,597	19,031,597
Warrant reserve	10	1,661,293	1,661,293
Share-based payment reserve	11	1,722,731	1,722,731
Equity component of convertible debt		176,251	176,251
Deficit		(16,686,360)	(20,663,822)
Total shareholders' equity		**5,905,512**	**1,928,050**
Total liabilities and shareholders' equity		**6,569,389**	**2,309,247**

Nature of operations and continuance of business (Note 1)
Subsequent events (Note 15)

Approved and authorized for issuance by the Board of Directors on July 30, 2026:

/s/ "Christopher Cherry"
Christopher Cherry, Director

/s/ "David Welch "
David Welch, Director

GOGO AI NETWORK INC.
(formerly MedBright AI Investments Inc.)
Condensed Interim Consolidated Statements of Operations and Comprehensive Income (Loss)
For the three months ended May 31, 2026 and 2025
(Unaudited - Expressed in Canadian dollars)

	Note	For the three months ended May 31, 2026 $	For the three months ended May 31, 2025 $
Investment income (loss)			
Interest income	5	(145)	-
Realized gain on investments	5	188,962	272,412
Unrealized gain (loss) on investments	5	3,828,159	(685,032)
Total investment income (loss)		4,016,976	(412,620)
Operating expenses			
Advertising and promotion		2,100	-
Consulting fees	8	18,936	47,629
Foreign exchange		-	46
General and administrative		195	16,984
Professional fees		11,094	7,949
Transfer agent and filing fees		3,540	3,928
Travel		3,097	-
Total operating expenses		38,962	76,536
Income (loss) before other items		3,978,014	(489,156)
Other items			
Interest expense		(552)	-
Total other items		(552)	-
Net income (loss) for the period		3,977,462	(489,156)
Basic income (loss) per share		0.04	(0.00)
Diluted income (loss) per share		0.04	(0.00)
Weighted average common shares outstanding – Basic		112,369,555	110,261,336
Weighted average common shares outstanding - Diluted		112,369,555	110,261,336

GOGO AI NETWORK INC.
(formerly MedBright AI Investments Inc.)
Condensed Interim Consolidated Statements of Changes in Shareholders' Equity
For the three months ended May 31, 2026 and 2025
(Unaudited - Expressed in Canadian dollars)

	Number of shares	Share capital $	Warrant reserve $	Share-based payment reserve $	Equity component of convertible debt $	Deficit $	Total shareholders' equity $
Balance, February 28, 2025	110,369,555	18,851,597	1,661,293	1,722,731	176,251	(19,678,592)	2,733,280
Net loss for the period	-	-	-	-	-	(489,156)	(489,156)
Balance, May 31, 2025	110,369,555	18,851,597	1,661,293	1,722,731	176,251	(20,167,748)	2,244,124
Balance, February 28, 2026	112,369,555	19,031,597	1,661,293	1,722,731	176,251	(20,663,822)	1,928,050
Net income for the period	-	-	-	-	-	3,977,462	3,977,462
Balance, May 31, 2026	112,369,555	19,031,597	1,661,293	1,722,731	176,251	(16,686,360)	5,905,512

GOGO AI NETWORK INC.
(formerly MedBright AI Investments Inc.)
Condensed Interim Consolidated Statements of Cash Flows
For the three months ended May 31, 2026 and 2025
(Unaudited - Expressed in Canadian dollars)

	For the three months ended May 31, 2026 $	For the three months ended May 31, 2025 $
Operating activities		
Net income (loss) for the period	3,977,462	(489,156)
Items not involving cash:		
Accretion on discount	-	-
Interest expense	552	-
Interest income	-	-
Realized gain (loss) on investments	(188,962)	(272,433)
Stock-based compensation	-	-
Write-off of loan receivable and interest	-	-
Write-off of accounts payable	-	-
Unrealized (gain) loss on investments	(3,828,159)	685,053
Changes in non-cash operating working capital:		
Prepaid expenses	(2,614)	5,629
Accounts payable and accrued liabilities	17,128	17,165
Net cash used in operating activities	(24,593)	(53,742)
Investing activities		
Proceeds from sale of investments	1,476,011	1,251,217
Purchase of investments	(219,730)	(1,105,545)
Net cash (used in) provided by investing activities	1,256,281	145,672
Financing activities		
Loan received	265,000	-
Net cash provided by financing activities	265,000	-
Change in cash and cash equivalents	1,496,688	91,930
Cash and cash equivalents (bank indebtedness), beginning of period	18,851	(109,247)
Cash and cash equivalents (bank indebtedness), end of period	1,515,539	(17,317)
Cash and cash equivalents consist of:		
Cash in bank	1,515,539	20,515
Cash in brokerage account	-	(37,832)
Total cash and cash equivalents (bank indebtedness)	1,515,539	(17,317)
Supplemental Disclosure of Cash Flow Information (Note 14):		
Interest paid	–	–
Transfer of investment for subsidiary shares	4,700,000	-
Income taxes paid	–	–

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

1. Nature of Operations and Continuance of Business

GoGo AI Network Inc. (formerly Medbright AI Investments Inc.) (the "Company") was incorporated as Vanguard Investments Corp. on March 20, 2001 and on May 10, 2011, continued the Company's registered jurisdiction from Alberta to British Columbia. The Company's head office is located at Suite 1600, 409 Granville Street, Vancouver, BC, V6C 1T2 and its shares are listed on the Canadian Securities Exchange ("CSE") under the symbol "VIN". During the year ended February 29, 2020, the Company became an investment issuer.

On November 7, 2023, the Company changed the name to 'Medbright AI Investments Inc.'. The Company commenced trading on CSE under the new trading symbol "MBAI" on November 9, 2023. On January 2, 2026, the Company changed the name to GoGo AI Network Inc. and commenced trading on CSE under the new trading symbol "GOGO".

These condensed interim consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. During the three months ended May 31, 2026, the Company incurred negative cash flow from operations. As at May 31, 2026, the Company has a working capital of $884,140 (February 28, 2026 – deficit of $332,482) and an accumulated deficit of $16,686,360 (February 28, 2026 – $20,663,822) since inception and expects to incur further losses in the development of its business. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing. Management is of the opinion that with its current cash and other funds that may be obtained from external financing that it has sufficient working capital to meet the Company's liabilities and commitments as they become due, although there is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company. These consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.

2. Basis of Presentation and Consolidation

Statement of Compliance

These condensed interim consolidated financial statements are prepared in accordance with International Accounting Standard ("IAS") 34, Interim Financial Reporting under IFRS Accounting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB"). These condensed interim financial statements follow the same accounting policies and methods of application as the most recent annual financial statements of the Company. These condensed interim consolidated financial statements do not contain all of the information required for full annual financial statements. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with the Company's most recent annual consolidated financial statements, which were prepared in accordance with IFRS as issued by the IASB.

Basis of Measurement

These condensed interim consolidated financial statements have been prepared on a historical cost basis, except for financial instruments measured at fair value. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting except for cash flow information.

Basis of Consolidation

These condensed interim consolidated financial statements include the accounts of GoGo AI Network Inc. (the "Company") and its subsidiaries. A subsidiary is an entity controlled by the Company. Control exists when the Company has power over an investee, is exposed or has rights to variable returns from its involvement with the investee, and has the ability to use its power over the investee to affect the amount of the Company's returns. All intercompany balances, transactions, revenues, and expenses have been eliminated upon consolidation.

2. Basis of Presentation and Consolidation (continued)

The Company's subsidiaries as at May 31, 2026, are as follows:

Name of Subsidiary	Jurisdiction of Incorporation	Functional Currency	Ownership Percentage
Vinergy Acquisition Corp.	USA	USD	100%
Vinergy Licensing Corp.	USA	USD	74%
1589675 B.C. Ltd.	British Columbia, Canada	CAD	100%

Functional and Presentation Currency

The condensed interim consolidated financial statements are presented in Canadian dollars, which is the functional currency of the Company and its Canadian subsidiaries. The functional currency of the US subsidiaries is the US dollar.

3. Material Accounting Policies

The preparation of financial data is based on accounting principles and practices consistent with those user in the preparation of the audited consolidated financial statements as at February 28, 2026. The accompanying unaudited condensed interim consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements for the year ended February 28, 2026.

4. Critical Accounting Estimated and Judgements

The preparation of these condensed interim consolidated financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets, liabilities, revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.

Going concern

At each reporting period, management exercises judgment in assessing the Company's ability to continue as a going concern by reviewing its performance, resources, and future obligations. The conclusion that the Company will be able to continue as a going concern is subject to critical judgments of management with respect to assumptions surrounding the short and long-term operating budgets, expected profitability, investment and financing activities and management's strategic planning. The assumptions used in management's going concern assessment are derived from actual operating results along with industry and market trends. Management believes there is sufficient capital to meet the Company's business obligations for at least the next 12 months, after taking into account expected cash flows, capital commitments, future financings and the Company's cash and cash equivalents position at period-end.

Fair value of investment in securities not quoted in an active market or private company investments

The determination of fair value of the Company's privately held investments at other than initial cost, is subject to certain limitations. Financial information for private companies in which the Company has investments may not be available and, even if available, that information may be limited and/or unreliable.

4. Critical Accounting Estimated and Judgements (continued)

The use of the valuation approaches described below may involve uncertainties and determinations based on management's judgment and any value estimated from these techniques may not be realized

Fair value of investment in securities not quoted in an active market or private company investments (continued)

or realizable.

Company-specific information is considered when determining whether the fair value of a privately held investment should be adjusted upward or downward at the end of each reporting period. In addition to company-specific information, the Company will also consider trends in general market conditions and the share performance of comparable publicly traded companies when valuing privately held investments.

The fair value of a privately held investment may be adjusted if:

i. There has been a significant subsequent equity financing provided by outside investors at a valuation different than the current value of the investee company, in which case the fair value of the investment is set to the value at which that financing took place.
ii. There have been significant corporate, political, or operating events affecting the investee company that, in management's opinion, have a material impact on the investee company's prospects and therefore its fair value. In these circumstances, the adjustment to the fair value of the investment will be based on management's judgment and any value estimated may not be realized or realizable.

i. The investee company is placed into receivership or bankruptcy.
ii. Based on financial information received from the investee company, it is apparent to the Company that the investee company is unlikely to be able to continue as a going concern.
iii. Release by the investee company of positive/negative operational results; and
iv. Important positive/negative management changes by the investee company that the Company's management believes will have a very positive/negative impact on the investee company's ability to achieve its objectives and build value for shareholders.

Adjustments to the fair value of a privately held investment will be based upon management's judgment and any value estimated may not be realized or realizable. The resulting values for non-publicly traded investments may differ from values that would be realized if a ready market existed. In addition, the amounts at which the Company's privately held investments could be currently disposed of may differ from the carrying value assigned.

Fair value of other instruments

Investments in warrants that are not traded on a recognized securities exchange do not have readily available market values. When there are sufficient and reliable observable market inputs, a market-based valuation technique such as the Black-Scholes valuation model ("Black-Scholes") is used.

Investment entity

Management has applied judgment in determining whether the Company meets the criteria required under IFRS 10, in order to be classified as an investment entity.

4. Critical Accounting Estimated and Judgements (continued)

Investment entity (continued)

The following are criteria within IFRS 10 – Consolidated Financial Statements, which the Company used to evaluate and determine that it continues to meet the definition of an Investment Entity:

- Obtain funds from one or more investors for the purpose of providing those investor(s) with investment management services;
- Commits to its investor(s) that its business purpose is to invest funds solely for returns from capital appreciation, investment income, or both; and
- Measures and evaluates the performance of substantially all its investments on a fair value basis.

The Company meets the criteria required to be considered an “investment entity” under IFRS 10 and as such, in the cases where the Company has control or significant influence over a company in its investment portfolio, the Company values such investments as financial assets at FVTPL.

5. Investments

Investments are recorded at their estimated fair value at the end of each reporting period. The fair values of the common shares of the publicly traded companies have been directly referenced to published price quotations in an active market. The fair value of investments in private companies will be based upon management’s judgement and different valuation techniques. The fair value of share purchase warrants of public companies are valued using the Black-Scholes option pricing model.

(Unaudited - Expressed in Canadian dollars)

5. Investments (continued)

Details of the Company's investments are as follows:

	Note	Number of common shares held	Investment Cost at May 31, 2026 $	Fair value February 28, 2026 $	Additions $	Dispositions $	Net change $	Fair value May 31, 2026 $
Public companies:								
Leef Brands Inc.		-	-	70,007	-	(76,239)	17,950	-
Rocket Doctor AI Inc (formerly Treatment.com AI Inc.)	(d)	-	-	618,235	219,730	(810,555)	(178,665)	-
Verses AI Inc.		31,986	277,020	36,525	-	(5,290)	(18,960)	28,148
Reconnaissance Energy Africa Ltd.		-	-	367,220	-	(450,479)	38,430	-
Private companies:								
Algo8 Industrial AI Inc.	(a)	5,604,091	900,000	900,000	-	-	3,800,000	4,700,000
Alphadroid India Private Limited	(c)	305	71,555	71,555	-	-	-	71,555
CWE European Holdings Inc.	(a)	1,250,000	150,000	-	-	-	-	-
First Person Ltd.	(a)	50,000	175,000	-	-	-	-	-
Healthcare Accretion Group Inc.	(b)	4,933,334	8,184,516	-	-	-	-	-
Mentorhead Incorporated	(a)	100,000	308,626	-	-	-	-	-
Other investments:								
Share purchase warrants		-	-	196,990	-	(133,448)	(134,571)	221,669
		11,969,716	10,066,717	2,260,532	219,730	(1,476,011)	3,524,184	5,021,372

During the three months ended May 31, 2026, the Company disposed of certain investments for total proceeds of $1,476,011 and realized a gain of $188,962 and the Company had an unrealized gain on investments of $3,828,159.

(Unaudited - Expressed in Canadian dollars)

5. Investments (continued)

	Note	Number of common shares held	Investment Cost at February 28, 2026 $	Fair value February 28, 2025 $	Additions $	Dispositions $	Net change $	Fair value February 28, 2026 $
Public companies:								
Leef Brands Inc.		359,008	104,113	152,252	-	(69,770)	(12,475)	70,007
Homeland Uranium Corp. (formerly Shift Rare Metals Inc.)		-	-	100,200	-	(78,985)	(21,215)	-
Netramark Holdings Inc.		-	-	717,44 0	112,190	(955,334)	125,704	-
Rocket Doctor AI Inc (formerly Treatment.com AI Inc.)	(d)	1,013,500	618,200	131,130	1,195,880	(931,800)	323,025	618,235
Tribe PPTY Technologies Inc.		-	-	-	135,000	(114,172)	(20,828)	-
Verses AI Inc.		34,786	224,220	580,328	1,917,979	(2,053,701)	(408,081)	36,525
Reconnaissance Energy Africa Ltd.		427,000	405,650	-	470,250	(56,470)	(46,560)	367,220
Private companies:								
Algo8 Industrial AI Inc.	(a)	4,500,000	900,000	900,000	-	-	-	900,000
Alphadroid India Private Limited	(c)	305	71,555	-	71,555	-	-	71,555
CWE European Holdings Inc.	(a)	1,250,000	150,000	-	-	-	-	-
First Person Ltd.	(a)	50,000	175,000	-	-	-	-	-
Healthcare Accretion Group Inc.	(b)	4,933,334	8,184,516	-	-	-	-	-
Mentorhead Incorporated	(a)	100,000	308,626	-	-	-	-	-
Other investments:								
Share purchase warrants		-	-	569,128	16,530	(1,740)	(386,928)	196,990
			11,141,880	3,150,478	3,819,384	(4,261,972)	(447,358)	2,260,532

During the year ended February 28, 2026, the Company disposed of certain investments for total proceeds of $4,261,972 and realized a gain of $520,056 and the Company had an unrealized loss on investments of $967,414.

Notes:

(a) The Company owns less than 10% interest in the investee as at May 31, 2026 and February 28, 2026
(b) The Company owns 49.33% interest in the investee as at May 31, 2026 and February 28, 2026.
(c) Advance for the acquisition of up to 305 equity shares of Alphadroid India Private Limited for US$50,000, pending issuance of shares as at February 28, 2026. During the three months ended May 31, 2026, the Company received 305 shares of Alphadroid.
(d) In October 2025, pursuant to the subscription agreement, the 340,000 special warrants of Rocket Doctor AI Inc. automatically converted into 340,000 common shares and 340,000 share purchase warrants for no additional consideration. As at February 28, 2026, there were nil special warrants outstanding.

(Unaudited - Expressed in Canadian dollars)

5. Investments (continued)

The investments measured at fair value on a recurring basis were presented on the Company's consolidated statements of financial position as at May 31, 2026 and February 28, 2026 as follows:

	Fair value measurements using			
	Quoted prices in active markets for identical instruments (Level 1) $	Significant other observable inputs (Level 2) $	Significant unobservable inputs (Level 3) $	Balance, May 31, 2026 $
Investments	28,148	221,669	4,771,555	2,260,532

	Fair value measurements using			
	Quoted prices in active markets for identical instruments (Level 1) $	Significant other observable inputs (Level 2) $	Significant unobservable inputs (Level 3) $	Balance, February 28, 2026 $
Investments	1,091,987	196,990	971,555	2,260,532

Level 2 fair value hierarchy

During the thee months ended May 31, 2026 and for the year ended February 28, 2026, the Company had the following activities:

	May 31, 2026	**February 28, 2026**
	$	**$**
Balance, beginning of year	196,990	569,128
Purchase of share purchase warrants	-	16,530
Proceeds on sale of warrants	(133,449)	(1,740)
Realized gain (loss) on sale of warrants	23,557	(621)
Fair value adjustments	134,571	(386,307)
Balance, end of year	221,669	196,990

Level 3 fair value hierarchy

The following table presents the changes in fair value measurements classified at Level 3 of the fair value hierarchy. The financial instruments are measured at fair value utilizing non-observable market inputs. The net realized loss on disposals of investments and the net change in unrealized loss on investments are recognized in the statements of loss and comprehensive loss.

	May 31, 2026	**February 28, 2026**
	$	**$**
Balance, beginning of year	971,555	900,000
Purchase at cost	-	71,555
Fair value adjustments	3,800,000	-
Transferred to Level 1	-	-
Balance, end of year	4,771,555	971,555

(Unaudited - Expressed in Canadian dollars)

5. Investments (continued)

Within Level 3, the Company includes private company investments which are not quoted on a recognized securities exchange. The key assumptions used in the valuation of these instruments include, but are not limited to, the value at which a recent financing was done by the investee company, company-specific information, trends in general market conditions and the share performance of comparable publicly traded companies. When a private company investment changes its status to a publicly-listed investment which meets Level 1 or Level 2 criteria, the investment is transferred out of the Level 3 fair value hierarchy. A transfer is recorded upon the occurrence of a liquidity transaction for an investee company, which includes, but is not limited to, a business combination between the entity and a public corporation pursuant to a reverse takeover, merger, amalgamation, arrangement, take-over bid, or an initial public offering of the entity. The transfers are recorded on the date that such a liquidity transaction is completed.

The following table presents the valuation techniques and the nature of significant inputs used to determine the fair values of the Level 3 investments as at May 31, 2026 and February 28, 2026:

	Fair value as at May 31, 2026 $	Method	Unobservable inputs	Range of inputs
Algo8 Industrial AI Inc.	4,700,000	Transaction price	Recent purchase price	N/A
Alphadroid India Private Limited	71,555	Transaction price	Recent purchase price	N/A
	4,771,555			

	Fair value as at February 28, 2026 $	Method	Unobservable inputs	Range of inputs
Algo8 Industrial AI Inc.	900,000	Transaction price	Recent purchase price	N/A
Alphadroid India Private Limited	71,555	Transaction price	Recent purchase price	N/A
	971,555			

Within Level 3 of the fair value hierarchy, for those investments valued based on recent financings, management has determined that there are no reasonably possible alternative assumptions that would change the fair value significantly as at May 31, 2026. A 10% change in the fair value of these investments would result in a corresponding change of approximately +/- $477,000 to the fair value of the investments. The sensitivity analysis is intended to reflect the uncertainty inherent in the valuation of these investments under current market conditions, and its results cannot be extrapolated due to non-linear effects that changes in valuation assumptions may have on the fair value of these investments. Furthermore, the analysis does not indicate the probability of such changes occurring, and it does not necessarily represent the Company’s view of expected future changes in the fair value of these investments.

(Unaudited - Expressed in Canadian dollars)

5. Investments (continued)

Loan receivable

On July 22, 2025, the Company entered into a promissory note with Rocket Doctor AI Inc. (formerly Treatment.com AI Inc.) ("Rocket AI") whereby the Company agreed to advance $70,000 to Rocket AI. The promissory note bears interest at a rate of 12% per annum and is unsecured and payable on demand. As at February 28, 2026, the Company had accrued $675 in accrued interest.

On August 12, 2025, the Company entered into a subscription agreement with Rocket AI. The $70,000 loan principal was applied to purchase 140,000 special warrants of Rocket AI at a price of $0.50 per warrant.

As at May 31, 2026 and February 28, 2026, the principal loan receivable balance was $Nil.

6. Accounts Payable and Accrued Liabilities

	May 31, 2026 $	February 28, 2026 $
Trade accounts payable	358,793	348,611
Accrued liabilities	40,084	32,586
	398,877	381,197

7. Loan Payable

On May 19, 2026, the Company entered into two shareholder loan agreements for an aggregate principal advance of $265,000. The loans are unsecured, bear simple interest at a rate of 6% per annum, and are due and payable upon written demand by lenders.

During the three months ended May 31, 2026, the Company recorded interest expenses of $552 in relation to these loans. As at May 31, 2026, the principal carrying value of the loan payable is $265,000 (February 28, 2026 - $Nil), and accrued interest of $552 is included in accounts payable and accrued liabilities.

8. Related Party Transactions

Key management compensation

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of members of the Company's Board of Directors and corporate officers. The Company entered into the following transactions with related parties during the three months ended May 31, 2026 and 2025.

(a) The Company incurred $13,650 (2025 – $10,500 in consulting fees to companies controlled by the Chief Financial Officer ("CFO") of the Company. As May 31, 2026, the Company owed $Nil (2025 – $3,150) to the company controlled by the CFO and $Nil (2025 - $4,000) directly to the CFO.

(b) The Company incurred $Nil (2025 – $31,500) in consulting fees to a director of the Company. As at May 31, 2026, the Company owed $500 (2025 – $500) to this director, which is included in accounts payable and accrued liabilities.

Subsequent to the three months ended May 31, 2026, on June 19, 2026, Brandon Kou resigned as a director.

(Unaudited - Expressed in Canadian dollars)

9. Share Capital

Authorized: Unlimited number of common shares without par value

There were no shares issued during the three months ended May 31, 2026.

Shares issued during the year ended February 28, 2026

On September 4, 2025, a total of 2,000,000 shares were issued pursuant to the exercise of RSUs (Note 11).

10. Share Purchase Warrants

The following table summarizes the continuity of share purchase warrants:

	Number of Warrants	Weighted average exercise price $
Balance, February 28, 2025	7,518,033	0.29
Expired	(7,518,033)	0.29
Balance, February 28, 2026 and May 31, 2026	-	-

As at May 31, 2026, the Company had no share purchase warrants outstanding.

11. Compensation Plans

Stock Options

The Company has established a stock option plan for directors, employees and consultants which is administered by the board of directors with full and final authority with respect to the granting of all options. The exercise prices shall be determined by the board, but shall, in no event, be less than the closing market price of the Company's shares on the grant date, less the maximum discount permitted under the TSX Venture Exchange's policies. The number of common shares issuable under the plan may not exceed 10% of the issued and outstanding common shares. In addition, the number of common shares which may be reserved for issuance to any one individual may not exceed 5% of the issued common shares on a yearly basis. Options may be exercisable for a maximum of ten years from the date of grant.

The following table summarizes the continuity of the Company's stock options:

	Number of options	Weighted average exercise price $
Outstanding, February 28, 2025	1,750,000	0.10
Expired	(500,000)	0.25
Outstanding, February 28, 2026 and May 31, 2026	1,250,000	0.04

(Unaudited - Expressed in Canadian dollars)

11. Compensation Plans (continued)

Additional information regarding stock options outstanding as at May 31, 2026 is as follows:

	Outstanding and exercisable		
Range of exercise prices $	Number of options	Weighted average remaining contractual life (years)	Weighted average exercise price $
0.035	1,250,000	3.68	0.035
	1,250,000	3.68	0.035

Restricted share unit plan

The Company has established a Restricted Share Unit Plan (“RSU Plan”) whereby the maximum number of common shares reserved for issue under the RSU Plan shall not exceed 10% of the issued and outstanding common shares of the Company.

On September 4, 2025, the Company issued 2,000,000 common shares to settle 2,000,000 RSUs to a director of the Company with a fair value of $0.09 per unit. The Company recognized $180,000 in share based compensation expense in respect of these RSUs (Note 9).

12. Risk Management

(a) Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit loss by placing its cash and cash equivalents with high credit quality financial institutions. The carrying amount of financial assets represents the maximum credit exposure.

(c) Foreign Exchange Rate Risk

Foreign currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company is not exposed to any significant foreign exchange rate risk.

(d) Interest Rate Risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to significant interest rate risk as it does not have any liabilities with variable rates.

(e) Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company currently settles its financial obligations out of cash. The ability to do this relies on the Company raising equity financing in a timely manner and by maintaining sufficient cash in excess of anticipated needs.

(Unaudited - Expressed in Canadian dollars)

13. Capital Management

The Company manages its capital to maintain its ability to continue as a going concern and to provide returns to shareholders and benefits to other stakeholders. The capital structure of the Company consists of cash and cash equivalents and equity comprised of issued share capital, warrant reserve, share-based payments reserve, and equity component of convertible debt.

The Company manages its capital structure and makes adjustments to it in light of economic conditions. The Company, upon approval from its Board of Directors, will balance its overall capital structure through new share issues or by undertaking other activities as deemed appropriate under the specific circumstances.

The Company is not subject to externally imposed capital requirements and the Company's overall strategy with respect to capital risk management remained unchanged from the year ended February 28, 2026.

14. Supplemental Cash Flow Information

	During the three months ended May 31, 2026 $	During the year ended February 28, 2026 $
Non-cash investing and financing activities:		
Fair value of common shares issued to settle RSUs	-	180,000
Transfer of investment in Algo8 to Subsidiary in exchange for Subsidiary shares	4,700,000	-
Investment in special warrants to settle loan receivable	-	70,000

During the three months ended May 31, 2026, on May 21, 2026, the Company transferred 5,604,091 common shares of Algo8 Industrial AI Inc. to its newly incorporated subsidiary, 1589675 B.C. Ltd., in exchange for 4,709,605 shares of the subsidiary. The transaction was a non-cash transfer settled at a fair market value of approximately $4.7 million.

During the year ended February 28, 2026, the Company subscribed to a private placement of Rocket AI for 140,000 special warrants at a price of $0.50 per special warrant for total consideration of $70,000. The subscription price was settled through the settlement of an outstanding loan receivable principal balance of $70,000 (Note 5).

15. Subsequent Events

On June 21, 2026, the Company entered into an arrangement agreement with Algo8 and the Subsidiary whereby the Company will distribute the Subsidiary's shares to the Company's shareholders and the Subsidiary will acquire all of the issued and outstanding securities of Algo8 in exchange for the Subsidiary's shares.